High-surface-area lyophilized composition containing arsenic for oral administration to patients

The development of an oral lyophilized arsenic trioxide formulation addresses the limitations of intravenous administration by providing comparable bioavailability and convenience, enhancing solubility and stability for treating hematological malignancies.

JP7885288B2Active Publication Date: 2026-07-06ケツァール·セラピューティクス·リミテッド·ライアビリティ·カンパニー
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2026-07-06

AI Technical Summary

Technical Problem

Conventional arsenic treatments for hematological malignancies require daily intravenous administration, which is inconvenient, risky, and costly, and there is no FDA-approved oral formulation available.

Method used

A lyophilized composition containing arsenic trioxide is developed, which can be administered orally, enhancing bioavailability and solubility through a process involving solubilization and freeze-drying, and optionally incorporating fillers and lubricants.

Benefits of technology

The oral formulation provides systemic bioavailability comparable to intravenous administration, offers a convenient and less dangerous method, and maintains stability for over three months, with improved solubility and bioavailability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007885288000047
    Figure 0007885288000047
  • Figure 0007885288000048
    Figure 0007885288000048
  • Figure 0007885288000049
    Figure 0007885288000049
Patent Text Reader

Abstract

To address the issues of the insolubility of As2O3 and the lack of bioavailability and provide a lyophilized composition comprising arsenic that makes it bioavailable, and further to provide methods for production thereof, and methods for treating malignancies such as tumor or cancer by orally administering the lyophilized composition comprising arsenic.SOLUTION: A method for preparing a lyophilized composition comprising arsenic (LCCA) comprises the steps for: (A) solubilizing As2O3 powder in an aqueous medium to form an As2O3 solution; and (B) lyophilizing the As2O3 solution.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art